Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
High frequency of hyperglycaemia observed during CAR T-cell treatment.
Tienstra M, de Boer JW, van Doesum JA, van Meerten T, van Dijk PR. Tienstra M, et al. Among authors: de boer jw. Diabet Med. 2023 Feb;40(2):e14969. doi: 10.1111/dme.14969. Epub 2022 Oct 17. Diabet Med. 2023. PMID: 36209376 Free PMC article. No abstract available.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Spanjaart AM, Pennings ERA, Mutsaers PGNJ, van Dorp S, Jak M, van Doesum JA, de Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, van der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, van Meerten T, Kersten MJ; Dutch CAR-T Tumorboard Consortium. Spanjaart AM, et al. Among authors: de boer jw. Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334. Cancers (Basel). 2023. PMID: 37686611 Free PMC article.
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.
de Boer JW, Pennings ERA, Kleinjan A, van Doesum JA, Spanjaart AM, Mutsaers PGNJ, Jak M, van der Poel MWM, Kuipers MT, Adam JA, Diepstra A, Koens L, van Dorp S, Vermaat JSP, Niezink AGH, Kersten MJ, van Meerten T. de Boer JW, et al. Blood Adv. 2023 Nov 14;7(21):6710-6716. doi: 10.1182/bloodadvances.2023010665. Blood Adv. 2023. PMID: 37639324 Free PMC article. No abstract available.
Semi-automated 18F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation.
Keijzer K, Niezink AGH, de Boer JW, van Doesum JA, Noordzij W, van Meerten T, van Dijk LV. Keijzer K, et al. Among authors: de boer jw. Comput Struct Biotechnol J. 2023 Jan 20;21:1102-1114. doi: 10.1016/j.csbj.2023.01.023. eCollection 2023. Comput Struct Biotechnol J. 2023. PMID: 36789266 Free PMC article.
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
de Boer JW, Keijzer K, Pennings ERA, van Doesum JA, Spanjaart AM, Jak M, Mutsaers PGNJ, van Dorp S, Vermaat JSP, van der Poel MWM, van Dijk LV, Kersten MJ, Niezink AGH, van Meerten T; Dutch CAR-T Tumorboard Consortium. de Boer JW, et al. Cancers (Basel). 2023 Nov 16;15(22):5443. doi: 10.3390/cancers15225443. Cancers (Basel). 2023. PMID: 38001703 Free PMC article.